Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation

被引:18
|
作者
Xu, Xi [1 ,2 ]
Ren, Jie [1 ,2 ]
Ma, Yinghe [1 ,2 ]
Liu, Hongting [1 ]
Rong, Quanjin [1 ]
Feng, Yifan [1 ]
Wang, Yameng [1 ]
Cheng, Yu [1 ]
Ge, Ruijia [3 ]
Li, Zhiyu [1 ,2 ]
Bian, Jinlei [1 ,2 ]
机构
[1] China Pharmaceut Univ, State Key Lab Nat Med, Jiangsu Key Lab Drug Design & Optimizat, Nanjing 210009, Jiangsu, Peoples R China
[2] China Pharmaceut Univ, Sch Pharm, Dept Med Chem, Nanjing, Jiangsu, Peoples R China
[3] Madeira Sch, Mclean, VA USA
基金
美国国家科学基金会; 中国国家自然科学基金;
关键词
Indoleamine 2,3-dioxygenase 1; inhibitor; virtual screen; cyanopyridine scaffold; hit optimisation; INDOLEAMINE 2,3-DIOXYGENASE; TRYPTOPHAN DEGRADATION; CRYSTAL-STRUCTURES; POTENT INHIBITORS; MOLECULAR DOCKING; DETAILED ANALYSIS; DENDRITIC CELLS; DERIVATIVES; DESIGN; EXPRESSION;
D O I
10.1080/14756366.2018.1480614
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
With the aim of discovering novel IDO1 inhibitors, a combined similarity search and molecular docking approach was employed to the discovery of 32 hit compounds. Testing the screened hit compounds has led to several novel submicromolar inhibitors. Especially for compounds LVS-019 with cyanopyridine scaffold, showed good IDO1 inhibitory activity. To discover more compounds with similar structures to LVS-019, a shape-based model was then generated on the basis of it and the second-round virtual screening was carried out leading to 23 derivatives. Molecular docking studies suggested a possible binding mode of LVS-019, which provides a good starting point for the development of cyanopyridine scaffold compounds as potent IDO1 inhibitor. To improve potency of these hits, we further designed and synthesised another 14 derivatives of LVS-019. Among these compounds, LBJ-10 showed improved potency compared to the hits and displayed comparable potency to the control GDC-0919 analogue. LBJ-10 can serve as ideal leads for further modifications as IDO1 inhibitors for cancer treatment.
引用
收藏
页码:250 / 263
页数:14
相关论文
共 50 条
  • [41] Reliable chromatographic assay for measuring of indoleamine 2,3-dioxygenase 1 (IDO1) activity in human cancer cells
    Sadok, Ilona
    Rachwal, Kamila
    Jonik, Ilona
    Staniszewska, Magdalena
    JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2021, 36 (01) : 581 - 592
  • [42] Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia
    Folgiero, Valentina
    Goffredo, Bianca M.
    Filippini, Perla
    Masetti, Riccardo
    Bonanno, Giuseppina
    Caruso, Roberta
    Bertaina, Valentina
    Mastronuzzi, Angela
    Gaspari, Stefania
    Zecca, Marco
    Torelli, Giovanni F.
    Testi, Anna M.
    Pession, Andrea
    Locatelli, Franco
    Rutella, Sergio
    ONCOTARGET, 2014, 5 (08) : 2052 - 2064
  • [43] Indoleamine 2,3-dioxygenase 1 (IDO1): an up-to-date overview of an eclectic immunoregulatory enzyme
    Pallotta, Maria Teresa
    Rossini, Sofia
    Suvieri, Chiara
    Coletti, Alice
    Orabona, Ciriana
    Macchiarulo, Antonio
    Volpi, Claudia
    Grohmann, Ursula
    FEBS JOURNAL, 2022, 289 (20) : 6099 - 6118
  • [44] Purification and kinetic characterization of human indoleamine 2,3-dioxygenases 1 and 2 (IDO1 and IDO2) and discovery of selective IDO1 inhibitors
    Meininger, David
    Zalameda, Leeanne
    Liu, Yichin
    Stepan, Lara P.
    Borges, Luis
    McCarter, John D.
    Sutherland, Claire L.
    BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS, 2011, 1814 (12): : 1947 - 1954
  • [45] Discovery of Highly Potent Benzimidazole Derivatives as Indoleamine 2,3-Dioxygenase-1 (IDO1) Inhibitors: From Structure-Based Virtual Screening to in Vivo Pharmacodynamic Activity
    Serafini, Marta
    Torre, Enza
    Aprile, Silvio
    Del Grosso, Erika
    Gesu, Alessandro
    Griglio, Alessia
    Colombo, Giorgia
    Travelli, Cristina
    Paiella, Salvatore
    Adamo, Annalisa
    Orecchini, Elena
    Coletti, Alice
    Pallotta, Maria Teresa
    Ugel, Stefano
    Massarotti, Alberto
    Pirali, Tracey
    Fallarini, Silvia
    JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (06) : 3047 - 3065
  • [46] Discovery of Carbono(di)thioates as Indoleamine 2,3-Dioxygenase 1 Inhibitors
    Kumazawa, Miyuki
    Tejima, Manabu
    Fukuda, Miwa
    Takeda, Shota
    Suzuki, Kenji
    Mizumoto, Yukiko
    Sato, Kakeru
    Waki, Minoru
    Miyachi, Hiroyuki
    Asai, Akira
    Takikawa, Osamu
    Hashimoto, Tomoko
    Ohno, Osamu
    Matsuno, Kenji
    ACS MEDICINAL CHEMISTRY LETTERS, 2021, 12 (02): : 211 - 216
  • [47] Mouse Mesenchymal Stem Cells Suppress Antigen-Specific TH Cell Immunity Independent of Indoleamine 2,3-Dioxygenase 1 (IDO1)
    Lanz, Tobias V.
    Opitz, Christiane A.
    Ho, Peggy P.
    Agrawal, Ankur
    Lutz, Christian
    Weller, Michael
    Mellor, Andrew L.
    Steinman, Lawrence
    Wick, Wolfgang
    Platten, Michael
    STEM CELLS AND DEVELOPMENT, 2010, 19 (05) : 657 - 668
  • [48] The Interplay between Indoleamine 2,3-Dioxygenase 1 (IDO1) and Cyclooxygenase (COX)-2 In Chronic Inflammation and Cancer
    Cesario, A.
    Rocca, B.
    Rutella, S.
    CURRENT MEDICINAL CHEMISTRY, 2011, 18 (15) : 2263 - 2271
  • [49] Dual Nicotinamide Phosphoribosyltransferase (NAMPT) and Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors for the Treatment of Drug-Resistant Nonsmall-Cell Lung Cancer
    Wang, Kaizhen
    Ye, Ke
    Zhang, Xiangyu
    Wang, Tianyu
    Qi, Zhihao
    Wang, Youjun
    Jiang, Sheng
    Zhang, Kuojun
    JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (01) : 1027 - 1047
  • [50] Identification of genetic variants in the human indoleamine 2,3-dioxygenase (IDO1) gene, which have altered enzyme activity
    Arefayene, Million
    Philips, Santosh
    Cao, Donghua
    Mamidipalli, Sudharani
    Desta, Zeruesenay
    Flockhart, David A.
    Wilkes, David S.
    Skaar, Todd C.
    PHARMACOGENETICS AND GENOMICS, 2009, 19 (06) : 464 - 476